Menu
$199.99 HP Stream 11 Laptop is On Sale

$199.99 HP Stream 11 Laptop is On Sale

Cara Delevingne Recorded Song with Pharrell

Cara Delevingne Recorded Song with Pharrell

Black Friday 2014 iPad Deals will be Amazing

Black Friday 2014 iPad Deals will be Amazing

Taylor Swift Releases New Song from 1989 Album Midnight

Taylor Swift Releases New Song from 1989 Album at Midnight

Oscar Pistorius gets Five Year Sentence after a Lengthy Trial

Oscar Pistorius gets Five Year Sentence after a Lengthy Trial

FDA Panel Once Again Rejects New Indication For J&J Drug

Jan 16 2014, 5:36pm CST | by , in News

FDA Panel Once Again Rejects New Indication For J&J Drug
Photo Credit: Forbes
 
 

The FDA’s Cardiovascular and Renal Drugs Advisory Committee once again turned down the supplemental new drug application for an acute coronary syndrome indication for Johnson & Johnson’s Xarelto (rivaroxaban). The nearly unanimous vote (10-0, with 1 abstention) was in line with a highly negative review from FDA staff members.


Although originally the subject of high praise when it first came out, the pivotal title="ATLAS ACS 2-TIMI 51: Rivaroxaban Beneficial in Low-Risk ACS Population">ATLAS ACS 2-TIMI 51 trial has been bedeviled by criticism since the FDA drew attention to the unusually large amount of missing trial data. Previous discussions of the trial at the FDA brought the word “missingness” into common usage in the medical community. Although J&J made efforts to supply some of the missing data this time around, ultimately the panel members agreed with the most recent assessment from the FDA reviewers that the large amount of still-missing data made it impossible to reach firm conclusions about the relative safety and efficacy of the drug in the setting of ACS.

Panel member Linda Fried, from the University of Pittsburgh, gave voice to a view adopted by many of the committee members. ATLAS, she said, was probably “an overall positive study” but, because of the large amount of missing data and the absence of a confirmatory study, was “not robust enough” to support the ACS indication. Speaking on behalf of the sponsor, cardiologists C. Michael Gibson and Marvin Konstam tried to persuade the panel to accept their multiple positive analyses of the trial. But panel members, including outspoken critics like Steve Nissen and Sanjay Kaul, left little doubt throughout the day’s meeting that they were unlikely to vote in favor of the new indication.

“We appreciate the thoroughness of the committee’s review and continue to believe rivaroxaban, in addition to the current standard of care, may help provide patients with ACS additional protection against life-threatening cardiovascular events such as death, heart attack and stroke. We will work with the FDA to address questions raised today,” said J&J’s Paul Burton, in a statement.

Source: Forbes

Shopping Deals

<a href="/latest_stories/all/all/31" rel="author">Forbes</a>
Forbes is among the most trusted resources for the world's business and investment leaders, providing them the uncompromising commentary, concise analysis, relevant tools and real-time reporting they need to succeed at work, profit from investing and have fun with the rewards of winning.

 

 

Comments

blog comments powered by Disqus